BACKGROUND: Vasoplegic syndrome, defined by hypotension despite normal or increased cardiac output, is associated with high mortality rate after cardiopulmonary bypass. Methylene blue (MB) is reported to ameliorate vasoplegic syndrome through the nitric oxide pathway. We hypothesized that early administration of MB would improve outcomes in patients with vasoplegic syndrome after cardiopulmonary bypass. METHODS: All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database. Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass. Multivariate logistic regression identified predictors of major adverse events among patients receiving MB. RESULTS: A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome. These patients had a higher incidence of comorbidities, and these cases were more commonly reoperative (76.1% versus 41.2%, p < 0.0001) and complex (70.3% versus 31.8%, p < 0.0001). The only difference in preoperative medications was that MB patients had a higher rate of amiodarone use (15.3% versus 2.2%, p < 0.0001). MB patients had significantly higher rates of postoperative complications, except atrial fibrillation. Early (operating room, 40.7%) versus late (intensive care unit, 59.3%) administration of MB was associated with significantly reduced operative mortality rate (10.4% versus 28.6%, p = 0.018) and risk-adjusted major adverse events (odd ratio 0.35, p = 0.037). CONCLUSIONS: Operative mortality rate is high in patients receiving MB for the treatment of vasoplegia after cardiopulmonary bypass. Early administration of MB improves survival and reduces the risk-adjusted rate of major adverse events in these patients.
BACKGROUND:Vasoplegic syndrome, defined by hypotension despite normal or increased cardiac output, is associated with high mortality rate after cardiopulmonary bypass. Methylene blue (MB) is reported to ameliorate vasoplegic syndrome through the nitric oxide pathway. We hypothesized that early administration of MB would improve outcomes in patients with vasoplegic syndrome after cardiopulmonary bypass. METHODS: All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database. Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass. Multivariate logistic regression identified predictors of major adverse events among patients receiving MB. RESULTS: A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome. These patients had a higher incidence of comorbidities, and these cases were more commonly reoperative (76.1% versus 41.2%, p < 0.0001) and complex (70.3% versus 31.8%, p < 0.0001). The only difference in preoperative medications was that MBpatients had a higher rate of amiodarone use (15.3% versus 2.2%, p < 0.0001). MBpatients had significantly higher rates of postoperative complications, except atrial fibrillation. Early (operating room, 40.7%) versus late (intensive care unit, 59.3%) administration of MB was associated with significantly reduced operative mortality rate (10.4% versus 28.6%, p = 0.018) and risk-adjusted major adverse events (odd ratio 0.35, p = 0.037). CONCLUSIONS: Operative mortality rate is high in patients receiving MB for the treatment of vasoplegia after cardiopulmonary bypass. Early administration of MB improves survival and reduces the risk-adjusted rate of major adverse events in these patients.
Authors: T Kofidis; M Strüber; M Wilhelmi; M Anssar; A Simon; W Harringer; A Haverich Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: Antonio Carlos Menardi; Fernanda Viaro; Walter Vilella de Andrade Vicente; Alfredo José Rodrigues; Paulo Roberto Barbosa Evora Journal: Arq Bras Cardiol Date: 2006-10 Impact factor: 2.000
Authors: Kirsten A Kortekaas; Jan H N Lindeman; Marlies E J Reinders; Meindert Palmen; Robert J M Klautz; Philip G de Groot; Mark Roest Journal: Interact Cardiovasc Thorac Surg Date: 2013-06-04
Authors: Isabella Werner; Fengwei Guo; Nicolai V Bogert; Ulrich A Stock; Patrick Meybohm; Anton Moritz; Andres Beiras-Fernandez Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240
Authors: David Katzianer; Keira Chism; Ataul M Qureshi; Ryan Watson; Howard Todd Massey; Andrew J Boyle; Gordon Reeves; Ilya Danelich Journal: J Cardiol Cases Date: 2019-09-17
Authors: Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni Journal: Intensive Care Med Date: 2018-06-04 Impact factor: 17.440
Authors: Michal Porizka; Petr Kopecky; Helena Dvorakova; Jan Kunstyr; Michal Lips; Pavel Michalek; Martin Balik Journal: Sci Rep Date: 2020-02-04 Impact factor: 4.379
Authors: Othmar Kofler; Maximilian Simbeck; Roland Tomasi; Ludwig Christian Hinske; Laura Valentina Klotz; Florian Uhle; Frank Born; Maximilian Pichlmaier; Christian Hagl; Markus Alexander Weigand; Bernhard Zwißler; Vera von Dossow Journal: J Clin Med Date: 2022-02-20 Impact factor: 4.241
Authors: Kristen M Tecson; Brian Lima; Andy Y Lee; Fayez S Raza; Grace Ching; Cheng-Han Lee; Joost Felius; Ronald D Baxter; Sasha Still; Justin D G Collier; Shelley A Hall; Susan M Joseph Journal: J Am Heart Assoc Date: 2018-05-17 Impact factor: 5.501
Authors: Walter Petermichl; Michael Gruber; Ina Schoeller; Kwahle Allouch; Bernhard M Graf; York A Zausig Journal: J Cardiothorac Surg Date: 2021-07-28 Impact factor: 1.637